Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors
Clinical trial NCT01199822 · COMPLETED
Trial details
- NCT number
- NCT01199822
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2010-09-01
- Primary completion
- 2012-01-01
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.